LifeNet Health and J&J MedTech Launch New Orthopedic Solution

LifeNet Health has launched PliaFX Pak in the US, in collaboration with Johnson & Johnson. PliaFX Pak is a versatile bone allograft that combines mineralized bone chips with precision-machined moldable demineralized fibers, offering surgeons an advanced solution to address voids and defects in orthopedic spine and trauma procedures, including fractures, fusions, and osteotomies. 
 
PliaFX Pak stands out due to its optimized handling properties. It includes interlocking fibers and bone chips to create a moldable and intact graft that can be transferred quickly and easily to the surgical site, eliminating the need for the tedious one-by-one transfer associated with traditional bone enhancing surgical efficiency.
 
PliaFX Pak has a 100% bone allograft featuring a proprietary blend of bone chips and demineralized cortical fibers processed with PliaFX Advanced Fiber Technology. This unique composition becomes moldable upon rehydration without the need for a carrier, enhancing both handling and performance. 
 
The solution also has long, rough cortical fibers that provide numerous contact points for platelet attachment, facilitating coagulation and stopping bleeding effectively. Its osteoconductive scaffold, with a large surface area and an interconnected network of bone fibers and chips, supports cell attachment and spreading, promoting bone and blood vessel formation. 
 
Its clinical applications span lumbar interbody fusion, anterior cervical discectomy and fusion (ACDF), opening wedge high tibial osteotomy (HTO), distal femur fracture, calcaneal fracture, and proximal humerus fracture.   
 
“LifeNet Health’s advanced fiber technology in PliaFX Pak sets a new standard for bone graft handling and performance. This innovation provides surgeons with a superior option that not only meets clinical needs but also enhances surgical efficiency,” said Rich Rice, Vice President, Orthopedics & CMF at LifeNet Health.
 
This new addition to the PliaFX family of bone void fillers, which already includes PliaFX Prime and PliaFX Strip, will be commercialized through J&J MedTech starting in August 2024.
 
This solution also fills a need in a fast-growing demineralized bone matrix (DBM) market, where estimates see 3-5% growth by 2028.